BIOMAT Database Logo BIOMAT Database Logo

Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma. 2014

Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Department of Medical Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.

OBJECTIVE Elevated serum beta-2 microglobulin (β2-M) has previously been reported in non-Hodgkin lymphoma (NHL) patients. This study examined the association between serum β2-M and the prognosis of NHL and analyzed its predictive value. METHODS A total of 287 NHL patients from Taiyuan, Shanxi, China, participated in a prospective cohort study between 2008 and 2011. Overall survival (OS) was compared between NHL patients with high and normal β2-M levels using the log-rank test. Three standard Cox regression models including the International Prognostic Index (IPI) score, β2-M or IPI score+β2-M as independent variables were constructed. The time-dependent receiver operating characteristic curves method and C index were used to examine the tendency of the models' predictive accuracy over time. RESULTS NHL patients with elevated β2-M values had worse OS (p<0.001) and higher mortality risk (HR=1.93, 95% CI 1.37-2.77, p<0.001) than patients with normal β2-M values. There were statistically significant differences between the C indexes for the models with IPI+β2-M, IPI or β2-M alone (p<0.001). CONCLUSIONS Our results demonstrated an association between serum β2-M and NHL prognosis. Combining β2-M with IPI may help to improve the prognostic accuracy of NHL.

UI MeSH Term Description Entries
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.
September 2014, Medical oncology (Northwood, London, England),
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma.
March 1983, European journal of cancer & clinical oncology,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
July 2002, Haematologica,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
November 2016, Oncotarget,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
March 2016, Hematological oncology,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma.
January 1991, Hematological oncology,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
May 1991, Annals of internal medicine,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens.
January 2005, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
The Prognostic Significance of the Serum p53 Protein Concentration in Chinese Patients with Non-Hodgkin Lymphoma.
December 2012, Turkish journal of haematology : official journal of Turkish Society of Haematology,
Li Wu, and Tong Wang, and Wei Gui, and Hualiang Lin, and Kaipeng Xie, and Hui Wang, and Tao Gao, and Xiuxiu Zhang, and Lei Liu, and Ting Han, and Yuan Tian, and Lifang Hou
Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era.
November 2016, Oncotarget,
Copied contents to your clipboard!